Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer.

MLA

Iizumi, Takashi, et al. “Acute Toxicity and Patient-Reported Symptom Score after Conventional versus Moderately Hypofractionated Proton Therapy for Prostate Cancer.” Journal of Medical Radiation Sciences, vol. 69, no. 2, June 2022, pp. 198–207. EBSCOhost, https://doi.org/10.1002/jmrs.551.

APA

Iizumi, T., Ishikawa, H., Sekino, Y., Tanaka, K., Takizawa, D., Makishima, H., Numajiri, H., Mizumoto, M., Nakai, K., Okumura, T., & Sakurai, H. (2022). Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer. Journal of Medical Radiation Sciences, 69(2), 198–207. https://doi.org/10.1002/jmrs.551

Chicago

Iizumi, Takashi, Hitoshi Ishikawa, Yuta Sekino, Keiichi Tanaka, Daichi Takizawa, Hirokazu Makishima, Haruko Numajiri, et al. 2022. “Acute Toxicity and Patient-Reported Symptom Score after Conventional versus Moderately Hypofractionated Proton Therapy for Prostate Cancer.” Journal of Medical Radiation Sciences 69 (2): 198–207. doi:10.1002/jmrs.551.